Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer.
Launched by UNIVERSITY GHENT · Oct 4, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female
- • Minimally 18 years old
- • Diagnosed with estrogen-receptor positive breast cancer
- • This must be a primary tumor
- Exclusion Criteria:
- • Male
- • Younger than 18 years old
- • Previous history of other tumors
About University Ghent
University Ghent is a prestigious Belgian research institution renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a multidisciplinary approach, the university fosters collaboration among leading experts in various fields, ensuring rigorous study design and ethical standards. University Ghent is dedicated to exploring new therapeutic modalities and enhancing healthcare outcomes, making significant contributions to both local and global health landscapes. Its state-of-the-art facilities and emphasis on research excellence position it as a pivotal sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ghent, East Flanders, Belgium
Ghent, East Flanders, Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported